Headquartered in South Lake Union, Seattle, Washington, Juno (NASDAQ: JUNO) is a clinical-stage company that is focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. They are developing cell-based cancer immunotherapies based on chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. They are founded on the vision that the use of human T cells as therapeutics will drive one of the next important phases in medicine.
Working at Slalom Consulting I was involved in all aspects of the project – Scoping, Planning, Design and Development. Our primary goals for the site:
Launch a new site under strict time constraints to coincide with their announced intent to IPO
Implement a new user friendly design
Implement a stable, and update-able CMS system to accommodate anticipated growth
Create a responsive layout
Implement robust News, Investor and HR areas
Coordinate (with NASDAQ) the launch of Investors area with timing of IPO, Dec. 2014